Table 2 Treatments and outcomes
From: Role of respiratory intermediate care units during the SARS-CoV-2 pandemic
COVID-19 treatment | |
Hydroxychloroquine | 73 (69%) |
Systemic corticosteroids | 66 (62%) |
Azithromycin | 60 (57%) |
Tocilizumab | 51 (48%) |
Anakinra | 22 (21%) |
Siltuximab | 5 (5%) |
Remdesivir | 5 (5%) |
Respiratory support in RICU | |
High flow oxygen nasal cannula | 33 (31%) |
Non-invasive ventilation | 15 (14%) |
Days since tracheostomy to decannulation (median [IQR]; n = 31) | 25.5 [19–34] |
Days since admission to decannulation (median [IQR]; n = 31) | 8 [5–12] |
NIV duration, days (median [IQR]; n = 14) | 4 [1–6.5] |
HFNC duration, days (median [IQR]; n = 32) | 5 [3–7] |
Renal replacement therapy | 9 (9%) |
Vasopressors | 3 (3%) |
Destination | |
Discharge to COVID-19 ward | 75 (71%) |
Transfer to ICU | 17 (16%) |
Death | 14 (13%) |
Outcomes | |
30-day mortality | 15 (14%) |
Global mortality at 90 days | 20 (19%) |
Days since admission to RICU (median [IQR]) | 13 [4–25.3] |
LOS in RICU (median [IQR]) | 7 [4–11] |
LOS (median [IQR]) | 34 [17–52] |
Days since admission to death | 27 [12–34] |